Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13078921 | 0.92 | PDK2 (0.37) | PDK2KDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12207337 | 0.90 | ADK (0.34) | ADKPDK2KDM4ENOX1LMNA | |
| SCHEMBL6725085 | 0.90 | ADK (0.34) | ADKPDK2KDM4ENOX1LMNA | |
| SCHEMBL6725073 | 0.88 | PDK2 (0.33) | ADKPDK2 | |
| SCHEMBL12207676 | 0.88 | PDK2 (0.34) | ADKPDK2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL12564882 | 0.88 | PDK2 (0.34) | ADKPDK2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL12690696 | 0.87 | PDK2 (0.34) | ADKPDK2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL14447296 | 0.86 | PDK2 (0.38) | ADKPDK2KDM4ENOX1LMNA | |
| SCHEMBL6725777 | 0.85 | PDK2 (0.32) | ADKPDK2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL12207288 | 0.84 | TDP1 (0.35) | KDM4ELMNASMN1; SMN2PSMB5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178216-B2 | Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178216-B2 | Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20090072718-A1 | Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2009-03-19 | — | — | US | disclosed |
| US-20090072718-A1 | Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090072718-A1 | Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative | CRY1, GRK1, CRY2 | ADK 2350/4885PDK2 625/4885KDM4E 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.